Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch

Talks Crucial To Launch Success

Executive Summary

GSK is gearing up for its most important new product launch in years and hopes US payers will buy into Arexvy’s likely higher price than Pfizer’s rival RSV vaccine.

You may also be interested in...

Stock Watch: Johnson & Johnson’s Q2 Helps Pharma Sentiment

Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.

Quick Listen: Scrip's Five Must-Know Things

In this week's episode of Five Must-Know Things: large M&A deals under regulatory review; surprise at Roche’s cardiovascular deal; BioNTech’s multiple China partnerships; GSK preps for US RSV vaccine launch; and a look at the dynamic multiple myeloma market.

GSK And Pfizer RSV Vaccines Get US Recommendation – But Big Decisions On Pricing Yet To Come

GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts